Dr. Han-Chung Wu’s research group in Academia Sinica recently generated a series of chimeric antibodies that can neutralize SARS-CoV-2 by binding to the spike protein receptor-binding domain (RBD). Two of the identified antibodies were combined in a cocktail therapy that shows remarkable ability to attenuate viral infection and disease progression in animal models. The work was published in 21, Oct, 2021 in the world-renowned journal, PLoS Pathogens.

Article Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009704